This study is to evaluate the safety and immunogenicity of a SARS-CoV-2 mRNA Vaccine as a heterologous booster dose in adults who completed 2 doses of inactivated vaccination through 12 months in China.

Start Date16 May 2022

Sponsor / Collaborator

Agna Biopharmaceutical Co., Ltd.

100 Clinical Results associated with SARS-CoV-2 mRNA vaccine(Argorna Pharmaceuticals)

100 Translational Medicine associated with SARS-CoV-2 mRNA vaccine(Argorna Pharmaceuticals)

100 Patents (Medical) associated with SARS-CoV-2 mRNA vaccine(Argorna Pharmaceuticals)

Literatures (Medical) associated with SARS-CoV-2 mRNA vaccine(Argorna Pharmaceuticals)

01 Jan 2023·Methods in Molecular Biology

Latest Trends in Nucleic Acids’ Engineering Techniques Applied to Precision Medicine

Article

Author: Pereira, Glaucia C

Nucleic acids are paving the way for advanced therapeutics. Unveiling the genome enabled a better understanding of unique genotype-phenotype profiling. Methods for engineering and analysis of nucleic acids, from polymerase chain reaction to Cre-Lox recombination, are contributing greatly to biomarkers' discovery, mapping of cellular signaling cascades, and smart design of therapeutics in precision medicine. Investigating the different subtypes of DNA and RNA via sequencing and profiling is empowering the scientific community with valuable information, to be used in advanced therapeutics, tracking epigenetics linked to disease. Recent results from the application of nucleic acids in novel therapeutics and precision medicine are very encouraging, demonstrating great potential to treat cancer, viral infections via inoculation (e.g., SAR-COV-2 mRNA vaccines), along with metabolic and genetic disorders. Limitations posed by challenges in delivery mode are being addressed to enable efficient guided-gene-programmed precision therapies. With the focus on genetic engineering and novel therapeutics, more precisely, in precision medicine, this chapter discusses the advance enabled by knowledge derived from these innovative branches of biotechnology.

01 Sep 2021·eBioMedicineQ1 · MEDICINE

Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis

Q1 · MEDICINE

ArticleOA

Author: Clarke, Candice ; Martin, Paul

During the course of the SARS-CoV-2 pandemic, patients established on in-center maintenance haemodialysis found themselves in a unique and unenviable predicament: deemed to be clin. extremely vulnerable to COVID-19 by virtue of their end stage kidney disease (ESKD), and yet unable to shield due to their need to regularly access a life-sustaining therapy in a healthcare setting.Renal healthcare providers around the world did their best to adapt in-center haemodialysis environments to safely deliver the service.Screening protocols and infection prevention measures were established, and infected patients were cohorted at specific dialysis centers where possible.Despite these efforts, both infection and mortality rates in this cohort of patients were high at up to 20% and 32%, resp..The advent of safe, effective SARS-CoV-2 vaccines was met with both relief and caution as patients with ESKD were excluded from the large phase III SARS-CoV-2 vaccine trials, and attenuated responses to vaccines (hepatitis B, influenza) is well documented in haemodialysis populations.

Journal of Korean Medical Science

Cytotoxic Lesion of the Corpus Callosum (CLOCCs) after SARS-CoV-2 mRNA Vaccination

Author: Youn, Taeho ; Yang, Heewon

A 22-yr-old previously healthy man visited the emergency department. He received the first dose of SARS-CoV-2 mRNA vaccine (BNT162b) 3-days prior coming to the hospital. He complained of febrile sensation and headache around the eyes and forehead.He was alert and neurol. examination showed that cranial nerves were grossly intact with both deep tendon reflexes and muscle strength being normal.

100 Deals associated with SARS-CoV-2 mRNA vaccine(Argorna Pharmaceuticals)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 1	CN	Agna Biopharmaceutical Co., Ltd.	16 May 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

SARS-CoV-2 mRNA vaccine(Argorna Pharmaceuticals)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation